Cortesi PA, Paolicelli D, Capobianco M, Cozzolino P, Mantovani LG. The Value and Sustainability of Ocrelizumab in Relapsing Multiple Sclerosis: A Cost-Effectiveness and Budget Impact Analysis. FE [Internet]. 2019 Jul. 10 [cited 2025 Jul. 23];20(1). Available from: https://provafe.seedstm.com/index.php/FE/article/view/1435